Conclusions
ADVANCED RENAL CELL CARCINOMA
These findings support lenvatinib plus pembrolizumab as a potential first‐line treatment for Japanese patients with advanced renal cell carcinoma.This subset analysis investigated efficacy and safety in Japanese patients with previously untreated advanced renal cell carcinoma randomized to receive lenvatinib plus pembrolizumab or sunitinib in the phase 3 CLEAR study. In general, efficacy favored lenvatinib plus pembrolizumab versus sunitinib. Findings were consistent with those of the overall CLEAR study population and support the combination as a potential first‐line treatment for Japanese patients with advanced renal cell carcinoma.
